Contributions
Abstract: PB1796
Type: Publication Only
Background
B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of CD5+ B cells in the peripheral blood and bone marrow. Prognosis of B-CLL is highly variable which depends on certain prognostic parameters. Novel prognostic markers and risk assessment models are fundamental to identify high risk patients who may need early treatment. The two tumour necrosis factor family proteins BAFF (TNFSF13B) and APRIL (TNFSF13) and their receptors [BAFF-R (TNFRSF13C), TACI (TNFRSF13B), BCMA (TNFRSF17)] play a critical role in the survival of normal B cells.
Aims
In this study, we aimed to investigate the impact of serum BCMA, TACI, BAFF and APRIL levels on prognosis of B-CLL.
Methods
A total of 129 newly diagnosed CLL patients [median age: 64(39-88); M/F: 85/44] and 26 healthy volunteers were enrolled in this study. Serum BCMA, TACI, BAFF and APRIL levels were measured at diagnosis using enzyme-linked immunosorbent assay (ELISA). The association with conventional prognostic markers and impact on survival were evaluated.
Results
Serum BAFF, TACI and BCMA levels were significantly lower in the patient group (p<0.001), while serum APRIL level did not differ significantly between the patient and control groups (p>0.05) (Table 1). Serum BAFF [(p=0,008; r=-0,236)] and BCMA [(p=0,042; r=-0,183)] levels were negatively correlated with Rai stage and serum BAFF level was higher in low-risk patients based on modified Rai staging system (p=0,059). Serum TACI level was higher in CD38 positive patients [(p=0,06; 0,17(0,1-0,86) vs 0,13(0,1-1,07)]. Age (p=0,002), Rai stage (p=0,005) and Modified Rai stage (p=0,051) were the significant factors which had an impact on overall survival in multivariate analysis.
Conclusion
As BAFF and APRIL display their main biological effects once they bind to their receptors and pass through the intracellular compartment, we consider that it may be more feasible to measure the intracellular levels of these molecules which may be more predictive for B-CLL prognosis. The association of TACI and CD38 expression may indicate the notable balance between proliferation and apoptosis, as CD38 is considered to be a proliferation marker in B-CLL. Further large and prospective studies analyzing the intracellular levels of these molecules are essential to validate the prognostic role of these particular biomarkers in CLL.
Session topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical
Keyword(s): Chronic Lymphocytic Leukemia, BAFF, prognosis
Abstract: PB1796
Type: Publication Only
Background
B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of CD5+ B cells in the peripheral blood and bone marrow. Prognosis of B-CLL is highly variable which depends on certain prognostic parameters. Novel prognostic markers and risk assessment models are fundamental to identify high risk patients who may need early treatment. The two tumour necrosis factor family proteins BAFF (TNFSF13B) and APRIL (TNFSF13) and their receptors [BAFF-R (TNFRSF13C), TACI (TNFRSF13B), BCMA (TNFRSF17)] play a critical role in the survival of normal B cells.
Aims
In this study, we aimed to investigate the impact of serum BCMA, TACI, BAFF and APRIL levels on prognosis of B-CLL.
Methods
A total of 129 newly diagnosed CLL patients [median age: 64(39-88); M/F: 85/44] and 26 healthy volunteers were enrolled in this study. Serum BCMA, TACI, BAFF and APRIL levels were measured at diagnosis using enzyme-linked immunosorbent assay (ELISA). The association with conventional prognostic markers and impact on survival were evaluated.
Results
Serum BAFF, TACI and BCMA levels were significantly lower in the patient group (p<0.001), while serum APRIL level did not differ significantly between the patient and control groups (p>0.05) (Table 1). Serum BAFF [(p=0,008; r=-0,236)] and BCMA [(p=0,042; r=-0,183)] levels were negatively correlated with Rai stage and serum BAFF level was higher in low-risk patients based on modified Rai staging system (p=0,059). Serum TACI level was higher in CD38 positive patients [(p=0,06; 0,17(0,1-0,86) vs 0,13(0,1-1,07)]. Age (p=0,002), Rai stage (p=0,005) and Modified Rai stage (p=0,051) were the significant factors which had an impact on overall survival in multivariate analysis.
Conclusion
As BAFF and APRIL display their main biological effects once they bind to their receptors and pass through the intracellular compartment, we consider that it may be more feasible to measure the intracellular levels of these molecules which may be more predictive for B-CLL prognosis. The association of TACI and CD38 expression may indicate the notable balance between proliferation and apoptosis, as CD38 is considered to be a proliferation marker in B-CLL. Further large and prospective studies analyzing the intracellular levels of these molecules are essential to validate the prognostic role of these particular biomarkers in CLL.
Session topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical
Keyword(s): Chronic Lymphocytic Leukemia, BAFF, prognosis